¤@.¤HÅ骺§K¬Ì¨t²Î ¤HÅ骺§K¬Ì¨t²Î¥i¥H¤À¦¨innate immunity ©Macquired immunity¨âÓ³¡¤À¡A·í¥~¨Ó¯fì¤J«I¤HÅé®É¡Aº¥ý¬O¥Ñ¥i¥H¿ëÃÑpathogen-associated molecular patterns (PAMPs)ªºinnate immunity¶}©l¶i¦æ¨¾¿mªº¤u§@¡A¦Ó·íinnate immunity¨S¦³¿ìªk§¹¥þªº²M°£¯fì®É¡A¤~¥Ñ¨ã¦³¿ëÃѱM¤@©Ê°ªªºacquired immunity¨Ó²M°£¥~¨Ó¤J«Iª«¡C ¤G.«D±M¤@©Ê§K¬Ì§@¥Î ¨Ò¦p¡G (1) ¥Ö½¤«Ì»Ù (2) µoª¢¤ÏÀ³¡G¬õ¡B¸~¡B¼ö¡Bµh¯gª¬ (3) §]¾½§@¥Î¡G§]¾½²ÓM ¤T.¤°»ò¥s°µ Toll-like receptors §K¬Ì²ÓM¤W¦³¤@¸s¨üÅé¡A¥Î¨Ó°»´ú¦UºØ¥~¨Óª«½è¡AºÙ°µ¡uÃþÅM¨üÅé¡v¡]toll-like receptor, TLR¡^¡A¥Dn°Ñ»P¥¼¤Þµo±M¤@©Ê§ÜÅ骺¡u«D¯S²§©Ê§K¬Ì¤ÏÀ³¡v¡C¤£¦PªºÃþÅM¨üÅé¦U¦³t³d°»´úªº¹ï¶H¡A¨Ò¦pTLR3t³d°»´ú¥~¨ÓªºÂùªÑRNA¯f¬r¡A¦Ó TLR4t³d·j´M²Óµßªº¤º¬r¯À¯×¦hÁÞ¡A¦ÓTrif§Y¬O³oÃþ¨üÅé©Ò¦@¥Îªº¶Ç°T¤À¤l¡C ¥|. Toll-¼Ë¨üÅé •Toll-¼Ë¨üÅé¡A¬°¤@¸û«O¦u¤£Åܪº¨üÅé³J¥Õ®a±Ú¡C¬O¼Ò¦¡ÃѧO¨üÅé(pattern recognition receptor , PRR)¡A¼sªx¤À¥¬©ó§K¬Ì²ÓM¡A¥iÃѧO¦hºØ¯fì·L¥Íª«¬ÛÃöªº¤À¤l¼Ò¦¡¡A¦p¦h¿}¡B¬O¥Íª«-·L¥Íª«¦@¦Pºt¤Æªº¦Ñ¬ÛÃÑ¡A©Ò¥H¤H±`¹ï·sªº¯fìÅé¸û§ô¤âµLµ¦¡A¦Ñ¬ÛÃѪº¥j¦Ñ¯fì¡A±`¤â¨ì¾à¨Ó¡A¤T¨â¤U´N·d©w¡C •TLR¦b¥Í¤Ñ§K¬Ì¤Î«á¤Ñ§K¬Ì¨t²Î¬Ò°_«n§@¥Î¡C TLRªº¨üÅ骺°tÅé(ligand)§Y§Ü¡Aì¥i¤À¥~·½©Ê¤Î¤º·½©Ê ¡E¥~·½©Ê¡Ð¨Ó¦Û¯fì·L¥Íª« ¡E¤º·½©Ê¡Ð¨Ó¦ÛÅ餺À³¿E©Î²Õ´¨ü·l©ÒÄÀ¥Xªº¤À¤l ¤. TLR¦b§K¬Ì½Õ±±¦³¦ó§@¥Î? •1.TLR¼sªx¦s¦b©ó¥ý¤Ñ§K¬Ì²ÓM¡C •2.¯fì¤J«I¡ATLR³Q¯fì¬ÛÃö¤À¤l¼Ò¦¡¿E¬¡¡A°£¤Àªc¤j¶q²ÓM¦]¤l¡A¤]¥iª½±µ¥[±j¥ý¤Ñ§K¬Ì¨t²Îªº±þµß¯à¤O¡A¾É¤W¥Ö²ÓM²£¥Í²ÓM¦]¤l¡AÁͤƦ]¤l¤Î§Ü·L¥Íª«¦h肽¡C •3.TLR¯à½Õ±±«á¤Ñ§K¬Ì²ÓM¡A³z¹L¾ðª¬²ÓM¤Î¤Àªcªº²ÓM¦]¤l¡A¹ïT²ÓM©MB²ÓM¦³¿E¬¡§@¥Î¡A¤]»¤¾É²£¥ÍÉC«¬¤zÂZ¯À¡C 4.TLR¯à½Õ±±§K¬Ì²ÓM¦Ü·P¬V³¡¦ì¡C 5.TLR½Õ±±Th1/Th2§K¬Ì¥¿Å¡ATLR©MPlR¨M©w¤£¦¨¼ôªº¾ðª¬²ÓM(DCi)¦¨¼ô¦¨½Õ¸`DC¡A²Ä¤@«¬DC©M²Ä¤G«¬DC¡A¨Ì¨Ï¦ÛµMT²ÓM¤À¤Æ¦¨½Õ¸`T²ÓM(Tre)¡A¤@«¬T²ÓM©M²Ä¤G«¬T²ÓMTreg¤ÀªcTGF-B©MIL-10§í¨îTh1©MTh2¡C ¤». ¤°»ò¥s°µ Toll-like receptors 1. Toll receptors¬O1988¦~¥ª¥k¦bªGÃÇÅ餺¥ýµo²{ªº¡A³o¨Çreceptors¦b±µ¦¬¨ì¥~¨Ó¯f쪺¨ë¿E«á¡A¥i¥H¤Þµo¤@³s¦êªºsignalling pathway¡A¨Ï±oimmune system¶}©l¦³©Ò¤ÏÀ³¡CÀH«á¡A¦b÷¨ÅÃþ°Êª«¤]µo²{©MToll¬Û¦ü«×·¥°ªªºreceptors¡AºÙ¬°Toll-like receptors (TLRs)¡C¥Ø«e©Òª¾ªºToll-like receptors ¦@¦³10ºØ¡A¤À§O±qTLR1¨ìTLR10¡A¥¦Ì¤À§O¿ëÃѤ£¦PªºPAMPs ¡C 2. ·íTLR¿ëÃѨì³o¨ÇPAMPs«á¡AÂÇ¥Ñreceptorsªºintracellular signalling domain, the Toll/interleukin-1 receptor (TIR) domain¥H¤Î¤U´åªºadaptor protein MyD88¡A±N°T®§¶Ç»¼¤U¥h¡A¨Ã¤Þµo²ÓM¤@¨Ç°ò¦]ªºªí²{¡C ¤C. Cell Types of Innate Immunity ¶Ý¤¤©Ê¥Õ¦å²y¦b³o¥ý¤Ñ©Ê§K¬Ì¤ÏÀ³´N¬O§êºt«D±`«n¤]¬O¥Dnªº¨¤¦â¡A¦]¬°¶Ý¤¤©Ê¥Õ¦å²y³q±`¬O³Ì¥ý³Q¬¡¤Æ¦Ó¥B³Ì§Ö¨ì¹F¤@¨Ç¥¿¦bµoª¢ªº§½³¡°Ï°ì¡A¯S§O¬O²Óµß©Êªº·P¬V©Ò³y¦¨¦´Á§K¬Ì¤ÏÀ³¡C ¶Ý¤¤©Ê¥Õ²ÓM¬O©è§Ü·L¥Íª««I¤Jªº²Ä¤@¹D¨¾½u¡A¨ã¦³ÅܧλP§]¾½¯à¤O¡A¦b©è§Ü¯e¯f¡B«OÅ@¾÷Åé¤è±«D±`«n¡C¶Ý¤¤©Ê¥Õ¦å²y¤§©Ò¥H¯à°÷¨t«¥ô¨Ã§¹¦¨¨Ï©R¦³¨â¶µ«nªº¥²³Æ±ø¥ó¡G 1.¶Ý¤¤©Ê¥Õ¦å²yn¯à°÷§Ö³t¦Ó¥B¥¿½T¤è¦Vªº²¾°Ê¨ì¥¿¦bµoª¢ªºP¯fì°Ï°ì¡C 2.¶Ý¤¤©Ê¥Õ¦å²y¦b¹ï§ÜP¯fµß¦³«Ü¦h¤wª¾¤è¦¡¡A°£¤Fª½±µ¹ïP¯f·½¶i¦æ§]¾½§@¥Î¡A¥t¥~ÁÙ¥]¬A¤Àªc¤@¨Ç¤À¸Ñ»Ã¯À¦pperoxidase (MPO)¡ALysozyme©MElastase¡A©ÎªÌ¬O¤Àªc¤@¨Ç¹L®ñ¤Æª«¦pROS¡ANO©MSuperoxide anion ¡C ¤E.«á¤Ñ©Ê§K¬Ì©Î¾AÀ³©Ê§K¬Ì ·í¤J«IªÌ¨S¦³³Q¨Å骺«D±M¤@©Ê¨t²Î¡]¥ý¤Ñ©Ê§K¬Ì¡^ºR·´®É¡A«á¤Ñ©Ê§K¬Ì´N·|±Ò°Ê¡C ƒá1.²O¤Ú²ÓM ƒá2.¥Dn²Õ´¬Û®e½Æ¦XÅé(MHC) ƒá3.§ÜÅé ¤Q.«á¤Ñ©Ê§K¬Ì «á¤Ñ©Ê§K¬Ì¬O¸g¥Ñ¦hºØÃþ«¬²ÓM¤Î¦¨¤À¬Û¤¬¨ó¤O§@¥Î©Òºc¦¨ªº¡C¦³¨âºØ¥DnÃþ«¬ªº«á¤Ñ©Ê§K¬Ì¡G²ÓM´C¤¶ªº§K¬Ì©M§ÜÅé´C¤¶ªº§K¬Ì¡C ¤Q¤G. ¥Dn²Õ´¬Û®e½Æ¦XÅémajor histocompatibility complex (MHC) ¡V¤HÃþMHC°ò¦]ºÙ¬°¤HÃþ¥Õ¦å²y§ÜìHLA, human leukocyte antigen (¦ì©ó²Ä¤»¹ï¬V¦âÅé) ¡V¤À¬°¨âÃþ •MHC class I ¡V°£¤F¸¢Åé¡B¤¤¼Ï¯«¸g¡BL½L²ÓM¥~¡A¨ä¥L²ÓM³£¦³ ¡V¯f¬r·P¬V²ÓM§Üì§e²{§@¥Î •MHC class II ¡V§Üì§e²{²ÓM¡G¾ð¬ð¡B¥¨¾½²ÓM¡BB²O¤Ú²y¡B¨ü²ÓM¿E¯À¨ë¿Eªº¦åºÞ¤º¾À²ÓM¡Bªí¥Ö²ÓM ¡VM¥~ªº§Üì§e²{§@¥Î ¡V¥\¯à¬°¬¡¤ÆT²O¤Ú²y ¤Q¤T.²O¤Ú²ÓM 1. ¤TºØ¥Dnªº²O¤Ú²ÓM°Ñ»P§K¬Ì¨t²Î¡CT²ÓM©MB²ÓM¦b«á¤Ñ§K¬Ì¨t²Î¤¤§êºt«n¨¤¦â¡A¦Ó¦ÛµM±þ¤â²ÓM«h°Ñ»P¥ý¤Ñ©Ê§K¬Ì¡C 2. ¬ù¦³¢µ¢¯¢Hªº²O¤Ú²ÓM¬O¢â²ÓM¡A¦¹²ÓM¦b°©Å褤µo¨|«á¾E²¾¨ì¯Ý¸¢¡A¦b¯Ý¸¢¦¨¼ô¨ÃÀò±o¯à¤O¥H¹ï§Ü·P¬V¡C 3.®Ú¾ÚB²ÓMªº¥\¯à¡A¤À¬°¤TºØÃþ«¬¡G¥®¸X(naive)B²ÓM ¦å¼ß²ÓM(plasma cells) ¡A °O¾Ð²ÓM(memory B cells ¤Q¤. T ²O¤Ú²ÓM ²ÓM¬rT²ÓM¡]cytotoxic T cell¡^¡G®ø·À¨ü·P¬Vªº²ÓM¡C³o¨Ç²ÓMªº¥\¯à´N¹³¤@Ó¡u±þ¤â¡v©Î²ÓM¬r¯À¨º¼Ë¡A¦]¬°¥¦Ì¥i¥H¹ï²£¥Í¯S®í§Üì¤ÏÀ³ªº¥Ø¼Ð²ÓM¶i¦æ±þ·À¡C²ÓM¬rT²ÓMªº¥Dnªí±¼Ð»x¬OCD8,¤]³QºÙ¬°±þ¤âT²ÓM¡C »²§UT²ÓM¡]helper T cell¡^¦b§K¬Ì¤ÏÀ³¤¤§êºt¤¤¶¡¹Lµ{ªº¨¤¦â¡G¥¦¥i¥H¼W¥ÍÂX´²¨Ó¿E¬¡¨ä¥¦Ãþ«¬ªº²£¥Íª½±µ§K¬Ì¤ÏÀ³ªº§K¬Ì²ÓM¡C»²§UT²ÓMªº¥Dnªí±¼Ð»x¬OCD4¡C T²ÓM½Õ±±©Î¡u»²§U¡v¨ä¥¦²O¤Ú²ÓMµo´§¥\¯à¡C¥¦Ì¬O¤wª¾ªºHIV¯f¬rªº¥Ø¼Ð²ÓM¡A¦b·R´þ¯fµo¯f®É·|«æ¼@´î¤Ö¡C ¤Q¤». Treg cells ½Õ±±T²ÓM •¦³¤@¸s½Õ±±T²ÓM(Regulatory T cells, Treg cells)¡A¥Dnªº¥\¯à¬Oºû«ù§K¬Ìªº¦ÛÅé§Üì@¨ü©Ê(self-tolerance)¡A©Ò¥H·íÅ餺Treg cellsµo¥Í¯Ê³´®É¡A·|¤Þ°_¦ÛÅé§K¬Ì¯e¯f¡C •¤j³¡¤À¦ÛµM²£¥ÍªºTreg cells·|ªí²{CD4¡BCD25©MFoxp3¡AFoxp3¬O½Õ±±Treg cellsµo¨|¤Î¥\¯àªº«nÂà¿ý¦]¤l¡C •¥Ø«e³\¦h¬ã¨sP¤O©óÀò±o¤j¶qªºFoxp3+ Treg cells¥Î¦bªvÀø¤W¡A¦ý¨ä¹ê²ÓM¤º½Õ±±Treg cells¦s¬¡ªº¾÷¨î¤´¥¼Âç²M¡C ¤Q¤C. Treg cells •½Õ¸`«¬T²ÓM(Treg cell)¥i¥H§í¨îTh1©MTh2ªº¬¡©Ê¡A¦³ÂIÃþ¦ü¨Å骺°jõX§í¨î§@¥Î¡ATreg cell¥i¥H³Q¯S²§©Êªº§Üì(¨Ò¦p¤G«¬½¦ì³J¥Õ)»¤¾É¡A²£¥Í@¨ü©Ê§@¥Î¡D •¤HÃþ½Õ±±T²ÓM¡]T regulatory cell,. Treg¡^ªº¥Dn¥\¯à¬O§í¨î§K¬Ì¤ÏÀ³¡Aªý¤î. ¹L±Ó¤Îµoª¢¡A¥HÁקK¦ÛÅé§K¬Ì¯e¯fµo ¥Í ¤Q¤K.½Õ±±T²ÓM ½Õ±±T²ÓMªººØÃþ¡G •1. CD4+CD25+ natural Treg¡G§Q¥ÎCTLA-4¡BGITR©ÎFasLµ¥²ÓM±µÄ²ªº¤è¦¡§í¨î¾ðª¬²ÓM¡Aªý¤î§K¬Ì²ÓM¬¡¤Æ¡C •2. CD4+ adaptive Treg¡G¤À¦¨Th3¥H¤ÎTr1¨âºØ¡A¤ÀªcIL-10©ÎTGF-bµ¥cytokine§í¨î¾ðª¬²ÓM¡Aªý¤î§K¬Ì¤ÏÀ³¡C •3. ¦bTreg¯Ê³´ªº¦Ñ¹«¥i¥H¬Ý¨ì¦ÛÅé§K¬Ì¯e¯f¡]¦p¡G²Ä¤@«¬¿}§¿¯f¡^¡B®ð³Ý¥H¤Î¹L±Ó¤ÏÀ³¡C ¤Q¤E. ¬°¬Æ»ò§ÜÅ骺ºØÃþ¤Î±M¤@©Ê¦p¦¹¦h©O¡H •§ÜÅé¤À¬°¤Ãþ¡]§Y¤ºØ ¦P«¬ isotypes¡^¡G§ÜÅ骺¦P«¬¬O¦]¬°¥¦¦³«í©w°Ï¦s¦b¡C§ÜÅ骺¤ºØÃþ«¬¬O¡G IgG, IgD, IgA, IgE, IgM ¡C¨C¤@ºØÃþ«¬»P¤£¦Pªº§K¬Ì¤ÏÀ³¦³Ãö¡C¨Ò¦p¡A IgG ±`±`§l¤Þ¨ã¦³ ²ÓM¬r©Ê ¡]cytotoxic¡^ ¡]±þ¶Ë©Ê¡^ªº T- ²ÓM¡A¨ä¯àºR·´¹v²ÓM¡C¹Ï¤¤Åã¥Üªº§ÜÅé¬O IgG1 «¬§ÜÅé¡C Ab repertoire might be 1012 - 1016 ¤G¤Q. Generation of immunoglobulin diversity in B cells before encounter with antigen 1.°£¤FB²ÓM¥H¥~ªºÅé²ÓM¡A¨ä¦³Ãö§K¬Ì²y³J¥Õªº°ò¦] ¬O§e¤ù¬qªº¡AµLªkªí²{¥X°ò¦]²£ª«¡C 2. B²ÓM¤º¦³§¹¾ãªº Ig °ò¦]¡A³Q¦³¶¶§Ç¦a¤À§G¦b¦U¬V¦âÅé¤W¥B¦b°ª«×Åܲ§°Ï¡A§t¦³ alternative version¡C ¤G¤Q¤@.Åé²ÓMÂI¬ðÅÜ •¬°²£¥Í§ÜÅ骺°O¾Ð«¬ B ²ÓM©Ò¿W¯Sªº²{¶H¡C •·í§K¬Ì¤ÏÀ³¦A¦¸ªº¹J¨ìthe same epitope, ¦b³Q¬¡¤Æªº¹Lµ{¤¤»Ýn¦³T-helper cellÄÀ©ñ²ÓM¿E¯À¡C •¦bÅܲ§°Ï¤×¨ä¬O°ª«×Åܲ§°Ï, ¨ä°ò¦]¦bCDR1, CDR2, and CDR3, ·|ÀH¾÷µo¥ÍÂI¬ðÅÜ¡C •¦p¦¹¥i¨Ï²£¥Íªº§ÜÅé§ó¨ã¿Ë©M¤O •¬ðÅÜ©M«²Õ¥i¥H¼W¥[¨ä¦h¼Ë©Ê ¤G¤Q¤G.¦ÛÅé§K¬Ì¯e¯f¤À¦¨¨â¤jÃþ (1) ¾¹©x±M¤@©Ê(organ-specific) : §K¬Ì¤ÏÀ³ª½±µ§ðÀ»³æ¿Wªº¾¹©x©Î¸¢Å骺¯S©w¥Ø¼Ð§Üì ¡C (2)¥þ¨©Ê¦ÛÅé§K¬Ì¯e¯f(systemic autoimmune) ¥þ¨©Ê¥Ø¼Ð§Üì ¤G¤Q¤T. ¦ÛÅé§K¬Ì¯e¯fªºì¦] •²Ä¤@ºØì¦]¡A¬O²Óµß©Î¯f¬rªº¶Ç¬V©Ò¤Þ°_ªº¥æ¤e§Üì¤ÏÀ³¡]cross-reaction¡^¡C¬Y¨Ç¯fìÅéµ²ºc»P±J¥D¦Û¨§Üì¬Û¦ü¡AºÙ¤§¤À¤l¬Û¦ü¾Ç»¡¡]molecular mimicry¡^¡C •²Ä¤GºØì¦]¡A¬O±J¥DÅ餺¥¿±`¥BÁôÂéʪº§Üì³QÄÀ©ñ¥X¨Ó¡A³Q§K¬Ì¨t²Îµø¬°¡u¥~¨Óªº¼Ä¤H¡v¡A¶i¦Ó§ðÀ»¤§ (¹jÂ÷§Ü쪺³QÄÀ©ñ)¡C •²Ä¤TºØì¦]¡A«h¬O¨ã¦³½Õ¸`§K¬Ì¨t²Î¥¿±`¹B§@ªº½Õ¸`©ÊT²ÓM¥X²{¥\¯à²§±`©ÒP (½Õ±±²ÓMÀ£§í§K¬Ì¥¢®Ä)¡C •²Ä¥|ºØì¦]¡A¦ÛÅé§Ü쪺§ïÅÜ¡AÀô¹Ò©ÎÃĪ«§@¥Î¤Þµo¦ÛÅé§Ü쪺§ïÅÜ¡C •²Ä¤ºØì¦]¡A¬OMHC°ò¦]ªº¼vÅT¡A¥ç§Y¿ò¶Ç(¿ò¶Ç¦]¯À)¡C •²Ä¤»ºØì¦]¡A²O¤Ú²ÓM¦¨¼ô¹Lµ{¤¤¿z¿ï¿ù»~¡C ¤G¤Q¥|.±`¨£ªº¦ÛÅé§K¬Ì¯e¯f •¬õ´³ ©Ê¯T½H •Ãþ·Àã©ÊÃö¸`ª¢ •µw¥Ö¯f •¦hµo©Ê¦Ùª¢»P¥Ö¦Ùª¢ •¦åºÞª¢ •×®æÄõSjogren¯gÔ¸sµ¥ ¤G¤Q¤.¤°»ò¬OÃþ·Àã©ÊÃö¸`ª¢ Ãþ·Àã©ÊÃö¸`ª¢¬O¤@ºØ¦ÛÅé§K¬Ì¤£¥þ©Ò¤Þµoªº¯e¯f¡A·|³y¦¨Ãö¸`ªººC©Êµoª¢¡A¦³®É¤]·|«I¥ÇÃö¸`ªº©P³ò²Õ´©ÎªÌ¬O¨Åé¨ä¥L¾¹©x¡C¤Þ°_Ãþ·Àã©ÊÃö¸`ª¢ªº¯u¥¿ì¦]¤£²M·¡¡C¬O¦ÛÅé§K¬Ì¿ù»~¦a«I¥Ç¦Û¤vÅ餺ªº²Õ´¡A¦Ó²£¥Íµoª¢¤ÏÀ³¡AÃþ·Àã©ÊÃö¸`ª¢¬O¤@ºØºC©Ê¯f¡A¯gª¬¥i¯à«ùÄò¼Æ¦~¡A¦Ó¥B·|¤ÏÂеo¥Í¡C ¤G¤Q¤».Ãþ·Àã©ÊÃö¸`ª¢¦³¤°»ò¯gª¬¡H Ãþ·Àã©ÊÃö¸`ª¢ªº¯gª¬¥Dn¦³Ãö¸`¬õ¡B¸~¡B¼ö¡Bµh¡CÃö¸`»øµw¡A¦³¹ïºÙ©Ê¡A¤@¯ë³£¥ý«I¥Ç¤â¡BµÃªº¤pÃö¸`¡A©P³ò²Õ´¦p¶´±a¡B¦Ù¸x©M¦Ù¦×¤]·|¦³¬Û¦Pªº¯gª¬¡C±wªÌ·|ı±o¯h¡A¹¼¤¤£¨Î¡A»´·Lµo¿N¡CÃö¸`¦Ù¦×»øµw¡A¦b²M±á¤×¨ä©úÅã¡A¦³¨Ç¯gª¬ÄY«ªº±wªÌ¡A¬Æ¦Ü·|µo¥ÍÃö¸`¯}Ãa¡BÅܧΪº±¡§Î¡C ¤G¤Q¤C.¤°»ò¼Ëªº¤H®e©ö¿©±wÃþ·Àã©ÊÃö¸`ª¢¡H ©Ê§O¤W¡A¥ÕºØ¤Hªº¿©±w¤ñ²v¸û¶ÀºØ¤H¨Ó±o°ª¡A¤k©Ê¸û¨k©Ê®e©ö¿©±w¦¹¯e¯f¡A¤k©Ê¥§¡°ª¥X¤T¿¥ª¥k¡A¯S§O¬O¥|¤Q·³¥H¤Wªº¤¤¦~°ü¤k¡A§ó¬OÃþ·Àã©ÊÃö¸`ª¢ªº°ª¦MÀI¸s¡C¦AªÌ¦³®a±Ú¿ò¯f¥vªº¥Á²³¡A¤]¸û¥±`¤H®e©ö¿©±wÃþ·Àã©ÊÃö¸`ª¢¡C
|